BBK Worldwide has raised $3 million to finance an expansion of its suite of eClinical software.
With pharma companies fretting about the cost of co-developing biomarkers for cancer drugs during early development, Merck staffers have proposed a novel solution: Pay for patients to have their tumors sequenced. Survey data suggest patients are open to the idea.
Apple rolled out the latest iteration of its mobile operating system this week, but users will have to wait until the end of the month to get hold of the much-discussed HealthKit platform.
The market for mHealth data aggregation platforms has become increasingly congested over the past year, with Apple and Google joining the more healthcare industry-focused Validic. Now Vivametrica has joined the space, outlining plans for a platform that fixes the inconsistencies in data from consumer mHealth products and combines them with outputs from medical devices.
AstraZeneca is following the well-trodden path of offshoring part of its IT to India. But unlike some of its peers--and in a reversal of its own strategy--the Big Pharma is adding in-house capacity and lessening its reliance on IT service providers.
With clinical trial sponsors spending a sizable chunk of their huge Phase III trial budgets on source data verification in return for questionable benefits, risk-based monitoring is an obvious target for TransCelerate BioPharma's R&D efficiency agenda. The Big Pharma consortium has further clarified its thinking on the topic in two research papers.
Observers tipped the arrival of Apple's long-awaited Watch to bring the worlds of health and tech closer than ever, but this week's announcement was notably light on medical uses. The failure to even mention HealthKit in the presentation has sparked discussion of Silicon Valley's wariness of healthcare regulators in the wake of 23andMe's run-in with the FDA.
Trialbee has added another large pharma to its list of clients, with AstraZeneca following Novo Nordisk in signing up to work with the online trial recruitment specialist. The AstraZeneca deal spans multiple regions, therapeutic areas and phases of clinical trials.
Medidata is providing the underlying technology, while Icon is contributing its pre-validated surveys.
The U.S. National Cancer Institute is working with Dell, Terascala and the Translational Genomics Research Institute to bolster its pediatric oncology research capabilities. The NCI ultimately hopes to use the new computing capabilities to discover new biomarkers and therapeutic targets for childhood cancers.
The study aims to recruit 40 people in the United Kingdom to wear watch-sized sensors on their belts. By placing the sensors around the body's center of mass the team from Imperial College London hope to gather data on each individual's position and walking speed.
Mayo Clinic and IBM have teamed up to apply cutting-edge technology to the age-old problem of enrolling patients into clinical trials. Starting next year Mayo Clinic will use IBM's supercomputer Watson to automatically match patients to clinical trials.
With the security of Apple's cloud storage system under scrutiny following reports linking it to the leak of private photographs, the company has barred apps that store health information from using the platform. The stipulation is one of several made by Apple as it tries to expand into healthcare without creating privacy problems or angering regulators.
The tech-driven reimagining of well-established clinical research and healthcare practices is continuing apace, with Propeller Health raising $14.5 million to develop its GPS-enabled inhaler. Users attach a small device to the end of their inhaler which tracks when and where a dose was administered.
The Harvard Medical School professor has long advocated for greater openness, with the sharing of his own data through the Personal Genome Project a standout example
Prenatal testing business Sequenom is the first company to buy the technology, which has applications in any setting in which genetic data needs mapping, sorting and deduplicating.
With pharma trade groups now committed to publishing the synopses of clinical study reports for some drugs, big-name consortium TransCelerate BioPharma has published a guide on how to redact documents.
While the outside world still has little idea what Google's biotech Calico is planning, AbbVie has seen enough to convince it to commit at least $250 million to the startup.
Takeda Pharmaceutical's United Kingdom subsidiary has begun working with C4X Discovery to improve its lead discovery and hit identification. The agreement is centered on C4XD's 3D drug technology, a nuclear magnetic resonance-based method of viewing the structure of a molecule.
IBM has opened up its Watson supercomputer to drug researchers through a new cloud-based service. And Big Pharma companies are already on board, with Johnson & Johnson and Sanofi among the early adopters of the technology.